Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Table 1 Variables included in the most widely used hepatocellular carcinoma staging systems
Staging system | Ascites | Tumor burden | Albumin | Bilirubin | INR | HE | AFP | PVT | EHS | PS | ALP |
Okuda | Yes | Yes | Yes | Yes | No | No | No | No | No | No | No |
CLIP | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No |
BCLC | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
GRETCH | No | No | No | Yes | No | No | Yes | Yes | No | Yes | Yes |
TNM 7th edition | No | Yes | No | No | No | No | No | Yes | Yes | No | No |
Table 2 Results of studies with molecular targeted therapies as first line in advanced hepatocellular carcinoma
Treatment | Trial | OS | TTP | Ref. |
Sorafenib | Phase III vs placebo | 10.7 mo vs 7.9 mo, P < 0.001; | 5.5 mo vs 2.8 mo, P < 0.001 | [10] |
(SHARP) | HR = 0.69; 95%CI: 0.55-0.87 | |||
Sorafenib | Phase III vs placebo | 6.5 mo vs 4.2 mo, P = 0.014; | 2.8 mo vs 1.4 mo, P = 0.0005; | [11] |
(Asia-Pacific) | HR = 0.68; 95%CI: 0.50-0.93 | HR = 0.57; 95%CI: 0.42-0.79 | ||
Sunitinib | Phase III vs sorafenib | 7.9 mo vs 10.2 mo, P = 0.0019; HR = 1.30; 95%CI: 1.13-1.50 | 4.1 mo vs 3.8 mo, one-sided P = 0.8312; | [31] |
(SUN) | two-sided P = 0.3082; HR = 1.13 | |||
Brivanib | Phase III vs sorafenib | 9.5 mo vs 9.9 mo, P = 0.3116; | 4.2 mo vs 4.1 mo, P = 0.853; | [32] |
(BRISK-FL) | HR = 1.07; 95%CI: 0.94-1.23 | HR = 1.01; 95%CI: 0.88-1.16 | ||
Linifanib | Phase III vs sorafenib | 9.1 mo vs 9.8 mo, P = NS; | 5.4 mo vs 4.0 mo, P = 0.001; | [33] |
HR = 1.05; 95%CI: 0.90-1.22 | HR = 0.759; 95%CI: 0.64-0.895 | |||
Erlotinib | Phase III erlotinib plus sorafenib and eorafenib plus placebo (SEARCH) | 9.5 mo vs 8.5 mo, P = 0.408; | 3.2 mo vs 4.0 mo, P = NS; | [36] |
HR = 0.929 | HR = 1.135; P = 0.18 |
Table 3 Results of studies with molecular targeted therapies as second line in advanced hepatocellular carcinoma
Treatment | Trial | OS | TTP/PFS | Ref. |
Brivanib | Brivanib vs placebo (BRISK-PS) | 9.4 mo vs 8.2 mo, P = 0.3307; | 4.2 mo vs 2.7 mo, P < 0.001; | [42] |
HR = 0.89; 95%CI: 0.69-1.15 | HR = 0.56; 95%CI: 0.42-0.76 | |||
Everolimus | Everolimus vs placebo (EVOLVE-1) | 7.6 mo vs 7.3 mo, P = 0.68; | 3.0 mo vs 2.6 mo, P = 0.01; | [44] |
HR = 1.05; 95%CI: 0.86-1.27 | HR = 0.93; 95%CI: 0.75-1.15 | |||
Ramucirumab | Ramucirumab vs placebo (REACH) | 9.2 mo vs 7.6 mo, P = 0.14; | 2.8 mo vs 2.1 mo, P < 0.0001; | [45] |
HR = 0.87; 95%CI: 0.72-1.05 | HR = 0.63; 95%CI: 0.52-0.75 |
Table 4 Principal ongoing studies in advanced hepatocellular carcinoma with new molecular targeted therapies
Study | Drug | Status |
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) vs sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma | Lenvatinib vs sorafenib | Active, not recruiting |
Study of regorafenib after sorafenib in patients with hepatocellular carcinoma (RESORCE) | Regorafenib vs placebo | Recruiting |
A study of dovitinib vs sorafenib in adult patients with hepatocellular carcinoma as a first line treatment | Dovitinib vs sorafenib | Completed (phase 2) |
A study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma | Nivolumab vs sorafenib | Recruiting |
Table 5 Assessment of target lesion response: Conventional Response Evaluation Criteria in Solid Tumors and modified Response Evaluation Criteria in Solid Tumors assessment for hepatocellular carcinoma following the American Association for the Study of Liver Diseases-Journal of the National Cancer Institute guideline
RECIST | mRECIST |
CR: Disappearance of all target lesions. | CR: Disappearance of any intratumoral arterial enhancement in all target lesions. |
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions. | PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. |
SD: Any cases that do not qualify for either partial response or progressive disease. | SD: Any cases that do not qualify for either partial response or progressive disease. |
PD: An increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. | PD: An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started. |
- Citation: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659
- URL: https://www.wjgnet.com/1007-9327/full/v22/i34/7645.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i34.7645